{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Organization",
      "@id": "https://www.regenerx.com/#organization",
      "name": "RegeneRx Biopharmaceuticals, Inc",
      "url": "https://www.regenerx.com/",
      "description": "RegeneRx Biopharmaceuticals, Inc Toggle navigation Company Overview Pipeline / Clinical Trials Business Development & Commercialization Investors Home RegeneRx Pipeline RegeneRx is a virtual biopharmaceutical company focused on tissue protection, repair and regeneration. While historically developing novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology, the Company’s primary focus is on Thymosin beta 4 (Tβ4) to treat ophthalmic indications such as neurotrophic keratitis (NK) and dry eye disease (DED). Currently, RegeneRx has active partnerships in four major territories: the U.S."
    },
    {
      "@type": "WebPage",
      "@id": "https://directory.websdocs.com/business/regenerx-biopharmaceuticals-inc#asg",
      "name": "RegeneRx Biopharmaceuticals, Inc ASG Directory Profile",
      "url": "https://directory.websdocs.com/business/regenerx-biopharmaceuticals-inc",
      "isPartOf": {
        "@id": "https://www.regenerx.com/#organization"
      },
      "description": "Public business information published by the WebsDocs ASG Directory."
    }
  ]
}